ESCRS - $2.2 million raised to build VR tools for amblyopia ;
ESCRS - $2.2 million raised to build VR tools for amblyopia ;

$2.2 million raised to build VR tools for amblyopia

Treatment for binocular vision disorders is available at more than 90 clinics across the world.

$2.2 million raised to build VR tools for amblyopia
Colin Kerr
Colin Kerr
Published: Tuesday, May 23, 2017
[caption id="attachment_8371" align="alignnone" width="800"]Image Credit: Vivid Vision Image Credit: Vivid Vision[/caption] Medical technology company Vivid Vision has announced that it has raised $2.2 million to build Virtual Reality (VR) tools that could be used to treat amblyopia. The company says its VR treatment for binocular vision disorders is available at more than 90 clinics across the world. Founded in 2014, Vivid Vision applies virtual reality to the field of vision care. Its founder and CEO, James Blaha, a programmer and lifelong sufferer of amblyopia, started the company after experimenting on himself. Before building the first prototype, Blaha couldn’t read with his weak eye or see in 3D. Since then, according to Vivid Vision, the vision in Blaha’s weak eye has improved to nearly 20/20. Vivid Vision launched its clinical vision therapy suite in late 2015 for optometrists and ophthalmologists and since then, the 90 clinics using it have treated more than 6,000 patients. On average, treatment lasts eight months, with patients coming one or two times a week to use the VR system. www.seevividly.com “It is a unique, far more efficient solution to treat Amblyopia, as well as a wide array of binocular vision dysfunction,” said Dan Fortenbacher, founder of Wow Vision Therapy, which has two locations in Michigan. “The progress the patient makes in breaking through suppression and developing 3D vision has been remarkable with Vivid Vision.”
Tags: amblyopia
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular

Long-awaited cellular therapies for corneal endothelial disease enter the clinic.

Read more...

Balancing Innovation and Safety

Ensuring access to advanced cell therapies amid regulatory overhaul.

Read more...

With Eyes on Its Future, ESCRS Celebrates Its Past

Winter Meeting offers opportunities to experiment with new concepts and formats.

Read more...

Best of ESCRS Winter Meeting 2024

Read more...

Following the New Generation

EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.

Read more...

Refocus on Multifocals

Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.

Read more...

Common Myths in Presbyopia Correction

Patient education key to satisfaction with refractive IOLs.

Read more...

Reversible Multifocality

Two-lens combination offers low-risk spectacle independence for cataract patients and presbyopes.

Read more...

Managing a Cataract Surgery Refractive Miss

Weighing the pros and cons of options for intraocular intervention.

Read more...

Unleashing OCT’s Full Potential

Performance of newest tool for corneal evaluation meets or beats older standard technologies.

Read more...

;